Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

Researchers discover new role of cellular signaling molecule involved in release of hunger hormone

Researchers at UT Southwestern Medical Center have identified a previously unknown role of a cellular signaling molecule involved in release of the "hunger hormone" ghrelin, a finding that could have implications for optimal treatment of children taking beta blockers.

23 Aug 2016

Increased production of feeling full hormone linked to reduced hunger and food intake in elderly people

A preliminary study might hold the key to why over-80s are prone to losing weight.

5 Aug 2016

Soy-ghretropin protein increases ghrelin levels and improves appetite

Researchers have discovered a protein that stimulates secretion of ghrelin, an appetite-stimulating hormone produced in the stomach.

19 Jul 2016

AMPK protein activated during fasting regulates hunger neurons in the brain

Neurons in the brain that control hunger are regulated by AMPK, a protein activated during fasting, report researchers from Tufts University School of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School in Neuron on July 6, 2016.

6 Jul 2016

CHLA study provides novel insights into the brain mechanisms linked to Prader-Willi syndrome

A study published in the journal Human Molecular Genetics by researchers at Children's Hospital Los Angeles provides novel insights into the brain mechanisms underlying the insatiable hunger and subsequent obesity in patients with Prader-Willi syndrome.

15 Jun 2016

Increasing ghrelin levels during hunger can negatively affect decision making capabilities

Never make a decision when you are hungry. The hormone ghrelin - that is released before meals and known to increase appetite - has a negative effect on both decision making and impulse control. Such were the results of a recently conducted study at Sahlgrenska University.

10 May 2016

Study offers clearer understanding of how obese people can sustain weight loss

Maintaining a stable weight loss is the biggest struggle for obese individuals, yet new research from University of Copenhagen have allowed researchers new insights into the complex processes involved in obesity and especially weight loss in obesity. It is now possible to offer overweight people a clearer understanding of how to sustain weight loss.

16 Apr 2016

Bariatric arterial embolization safe, effective in sustaining weight loss in severely obese people

Findings from the early phase of a clinical trial led by Johns Hopkins investigators indicates that a new, minimally invasive weight loss treatment known as bariatric arterial embolization is safe and effective in sustaining weight loss in severely obese people.

4 Apr 2016

Bariatric arterial embolization could offer viable, safe alternative to surgical weight-loss treatments

A safe, new, minimally invasive treatment, developed by interventional radiologists, led to sustained weight loss in severely obese people, according to research presented at the Society of Interventional Radiology's 2016 Annual Scientific Meeting. Researchers said the treatment--bariatric arterial embolization (BAE)--could offer individuals a viable, safe alternative to surgical weight-loss treatments.

4 Apr 2016

Exercise more effective than food restriction in helping reduce daily calorie consumption

Scientists at Loughborough University have found exercising is more effective than food restriction in helping limit daily calorie consumption.

9 Mar 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

Irregular sleep schedules linked to adverse metabolic health in midlife women

A new study suggests that frequent shifts in sleep timing may be related to adverse metabolic health among non-shift working, midlife women.

1 Feb 2016

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Interaction between two brain proteins has substantial effect on memory formation

In a new study that could have implications for future drug discovery efforts for a number of neurodegenerative diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have found that the interaction between a pair of brain proteins has a substantial and previously unrecognized effect on memory formation.

20 Nov 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Rhythm Metabolic completes $40 million Series A financing

Rhythm announced today the completion of a $40 million Series A financing for its subsidiary, Rhythm Metabolic, Inc., which is developing setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway.

13 Aug 2015

Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris Inc. announced today that it has executed a definitive agreement with Ergomed PLC, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

25 Jun 2015

Rhythm announces initiation of two setmelanotide Phase 2 trials for treatment of PWS, POMC-null obesity

Rhythm announced today the initiation of two Phase 2 clinical trials focused on evaluating the safety and effectiveness of setmelanotide (RM-493), the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of Prader-Willi Syndrome (PWS) and POMC-null obesity.

4 Jun 2015

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015